JFG
PYXS icon

Jefferies Financial Group’s Pyxis Oncology PYXS Stock Holding History

Jefferies Financial Group’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,000
Closed -$18.4K – 2118
2025
Q4 		$18.4K Buy
+16,000
New +$56.4K ﹤0.01% 1801

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jefferies Financial Group's PYXS Position: Q1 2026 in Review

Jefferies Financial Group sold out of Pyxis Oncology (PYXS) in Q1 2026, closing a stake of 16,000 shares — an estimated $18.4K sold.

Jefferies Financial Group first reported a position in PYXS in Q4 2025 and held it in 1 quarter. The position peaked at $18.4K in Q4 2025. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Jefferies Financial Group reported no remaining Pyxis Oncology position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 16,000 Pyxis Oncology shares in Q1 2026, an estimated $18.4K.
  • Jefferies Financial Group first reported a position in Pyxis Oncology in Q4 2025 and held it in 1 quarter.
  • Jefferies Financial Group's Pyxis Oncology position peaked at $18.4K in Q4 2025.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.